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Summary 
Aims The DETECT study was performed to obtain representative data about the frequency, 
distribution, and treatment of patients with coronary artery disease (CAD) in the primary care setting 
in Germany.  
Methods and results The DETECT study was a cross-sectional clinical- epidemiological survey of a 
nationally representative sample of 3795 primary care offices and 55 518 patients. Overall, 12.4% of 
patients were diagnosed with CAD. Stable angina pectoris and myocardial infarction were the most 
frequent (4.2%) subgroups, followed by status post (s/p) percutaneous coronary interventions (PCI, 
3.0%) and s/p coronary bypass surgery (2.2%). Patients with CAD were prescribed AT1 receptor 
antagonists (in 19.4% of cases), beta blockers (57.2%), ACE inhibitors (49.9%), antiplatelet agents 
(52.7%), statins (43.0%), and long-term nitrates (24.5%). When comparing all CAD patients with 
social health care insurance to those who had private insurance, private patients had significantly 
higher rates of revascularisation procedures and use of preventive medications.  
Conclusion Great potential remains for improving secondary prevention in primary care in Germany 
to reduce the risk of further coronary or vascular events, especially in patients with social health care 
insurance.  
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Introduction 
 
Cardiovascular disease is a major cause of death in most European populations [1, 2]. In 
Germany, the most common causes of death in 2003 were chronic ischaemic heart disease 
(19.1%) and acute myocardial infarction (7.5%, Table 1) [3]. More women than men die from 
coronary artery disease (CAD). Therefore, in women too, CAD is the leading cause of death. 
The chance a German woman will die from CAD is seven times higher than the chance she’ll 
die from breast cancer (Table 1).  
 
In addition to coronary bypass surgery and percutaneous coronary interventions (PCI) [4, 5], 
treatment with appropriate medications can reduce mortality and/or morbidity in patients with 
CAD. Examples include platelet inhibitors, beta blockers, ACE inhibitors, and statins [1]. The 
recent survey of the European Society of Cardiology (ESC) on coronary revascularisation in 
5619 patients revealed that 95% received antithrombotic drugs, 74% received beta blockers, 
57% received ACE inhibitors, and 67% received statins at discharge [5]. Another recent ESC 
survey covering 3779 patients with stable angina showed that 78% of these patients received 
aspirin, 67% received beta blockers, 37% received ACE inhibitors, and 48% received statins 
[6]. In this European survey, however, only 144 patients from Germany were enrolled.  
 
The existing data regarding the prevalence of coronary heart disease in Germany are severely 
limited. Therefore, the purpose of the DETECT study was to obtain representative data about 
the frequency, distribution, and treatment of patients with CAD in the German primary care 
setting.  
Methods 
 
DETECT (Diabetes cardiovascular-risk Evaluation: Targets and Essential data for 
Commitment of Treatment) is a three-stage, cross-sectional clinical-epidemiological study 
with a prospective-longitudinal component in a nationally representative sample of 3795 
primary care settings and 55 518 patients. The overall physician response rate to the survey 
was 95.5%. A standardised assessment was completed for each patient, including diagnostic 
screening measures (i.e., blood pressure, heart rate, body mass index, and waist 
circumference) and questionnaires were completed for patients and their physicians. A 
subsample of 7519 patients also completed a standardised laboratory screening program with 
followup after 12 months. Data were weighted to adjust for non-response, regional 
distribution, and attrition. Further details about the study have been published previously [7, 
8].  
 
All prevalence estimates reported in this paper were based exclusively on clinical diagnoses 
or specifications rated as ‘definite’ by the treating physician (n=55 518). Patients with a 
definite diagnosis of CAD were placed into the following six subclassifications: stable angina, 
unstable angina, myocardial infarction, PCI, coronary bypass surgery, and other. All 
physicians in DETECT practiced in the primary care setting in Germany.  
 
Within the standardised clinical assessment, physicians supplied data about the actual drug 
therapy the patient received. All prescription rates were based on patients with the definite 
diagnosis of CAD receiving a known actual medication (n=6569). Regarding the prescription 
rates for CAD patients with a different number of comorbid diseases, just the following 
comorbid diseases were considered: Diabetes mellitus, hypertension, and hyperlipidaemia. 
Whereas the diagnoses of hypertension and hyperlipidaemia were based solely on a 
physician’s clinical diagnosis, a patient was considered to have diabetes mellitus either if the 
patient was diagnosed clinically or if the patient received a prescription for an antidiabetic 
drug. The prevalence estimates derived from the study were based on the physician diagnoses. 
Using descriptive statistics, we compared the distributions of variables among all categories. 
Associations were estimated using logistic regression models. All statistical analyses were 
conducted with the software package STATA 8 [9].  
 
 
Results 
 
Prevalence of CAD 
 
Table 2 shows the prevalence of CAD and its subgroups broken out by age and gender. 
Overall, 12.4% of patients (6895/55 518) were diagnosed with CAD. Stable angina pectoris 
and myocardial infarction were the most frequent subgroups (4.2%), followed by s/p PCI 
(3.0%), and s/p coronary bypass surgery (2.2%). The ratio between stable angina and unstable 
angina was 3.8. Table 2 also reveals an age-related increase in all diagnoses and 
specifications. Furthermore, the prevalence rates for all diagnoses and specifications were 
higher in men compared to women in most age groups. 
 
Medications in patients with CAD 
 
Table 3 lists the intake frequency of antiplatelet drugs, beta blockers, ACE inhibitors, AT1 
receptor antagonists, statins, and long-term nitrates in patients with CAD, both as a group and 
within each subgroup. The prescription rates of these drugs, with the exception of AT1 
receptor antagonists and long-term nitrates, showed a trend toward higher use in patients after 
myocardial infarction, PCI, and coronary bypass surgery than in patients with stable or 
unstable angina.  
 
We observed significant differences in prescribed medications between CAD patients with 
social health care insurance and those with private health care insurance. Whereas CAD 
patients with social health care insurance were prescribed ACE inhibitors (social: 50.3%; 
private: 41.0%; OR=0.48; P<0.001) and long-term nitrates (social: 25.0%; private: 16.2%; 
OR=0.41; P<0.0001) more frequently than CAD patients with private health insurance, the 
opposite was true for AT1 receptor antagonists (social: 19.1%; private: 29.5%; OR=1.35; 
P<0.001), beta blockers (social: 57.1%; private: 63.8%; OR=0.76; P<0.001), antiplatelet 
agents (social: 52.5%; private: 56.1%; OR=0.75; P<0.001), and statins (social: 42.6%; 
private: 50.6%; OR=0.93; P<0.173).  
 
Male (m) patients received drugs fromthe following classes significantly more oftenthan 
female (f) patients: beta blockers (m: 60.8%; f: 52.3%; OR=1.26; P<0.001), ACE inhibitors 
(m: 53.0%; f: 45.7%; OR=1.50; P<0.001), antiplatelet agents (m: 57.2%; f: 46.5%; OR=1.85; 
P<0.001), and statins (m: 46.3%; f: 38.5%; OR=1.62; P<0.001). Female patients received 
AT1 receptor antagonists (m: 18.1%; f: 21.2%; OR=1.19; P<0.001) and long-term nitrates (m: 
23.5%; f: 25.8%; OR=1.55; P=0.000) significantly more frequently than male patients.  
 
Figure 1 shows differences in medication groups according to age and gender. For all 
medication groups, a relationship between prescription rates and age is clearly visible – most 
impressive in a linear manner for nitrates.  
 
Figure 2 lists the prescription rates for CAD patients with the comorbid diseases diabetes 
mellitus, hypertension, and hyperlipidaemia. It is statistically significant that physicians 
prescribe more secondary preventive medications in CAD patients with a higher comorbidity 
(P<0.0005 for all medications except nitrates). 
 
Revascularisation rates in patients with CAD 
 
CAD patients underwent PCI and coronary bypass surgery in 23.8% and 17.4% of cases, 
respectively. After PCI, 15.9% of patients still had stable angina compared to 9.6% after 
coronary bypass surgery. The highest revascularisation rates were observed in patients with 
s/p myocardial infarction (42.3% in PCI and 29.7% in coronary bypass surgery). Male CAD 
patients received PCI and coronary bypass surgery more often than female CAD patients 
(PCI: 29.5% vs 16.0%, OR=2.19, P<0.001; coronary bypass surgery: 23.1% vs 9.8%, 
OR=2.77, P<0.001). CAD patients with private health care insurance received PCI and 
coronary bypass surgery more often than CAD patients with social health insurance (PCI: 
33.7% vs 23.3%, OR=0.60, P<0.001; coronary bypass surgery: 22.7% vs 17.2%, OR=0.71, 
P=0.016).  
 
 
 
 
 
 
 
 
 
Discussion 
 
Prevalence of CAD 
 
According to the results of the DETECT study, nearly every eighth patient in German primary 
care offices is a patient with established CAD. As such, effective secondary prevention is of 
utmost importance. Comparing the prevalence of CAD in primary care offices in the 
DETECT study with the prevalence of CAD in the general population in the German Federal 
Survey [10], the DETECT study found slightly higher prevalence rates (Fig. 3). In DETECT, 
stable angina was 3.8 times as frequent as unstable angina. This result is comparable to the 
ratio of 4.55 that was calculated by the Equinox Group [11]. It should be noted as a limitation 
that the prevalence rates – with the exception of diabetes mellitus – were based exclusively on 
physician diagnoses. Given this limitation, the actual prevalence would be expected to be 
slightly higher than the reported rates.  
 
Medication prescription rates 
 
A recently published study showed that the use of multiple evidence-based classes of 
cardiovascular medications (i.e., antiplatelet, lipid-lowering, beta blockers, and ACE 
inhibitors) is associated with improved outcome (free of death or myocardial infarction) [12]. 
In our own experience in a single-centre survey in patients undergoing PCI in the year 2000, 
89% of the referred patients were on antithrombotic medications, 65% were on beta blockers, 
43% were on ACE inhibitors, and 46% were on statins [13]. The corresponding ranges from 
eleven studies of inpatients published in the period between 1997 and 2000 were 77–100% for 
antithrombotic medications, 30–80% for beta blockers, 10–72% for ACE inhibitors, and 13–
77% for statins [13].  
 
The pivotal data for Europe regarding prescription rates in CAD patients before hospital 
discharge were derived from the EUROASPIRE I and II studies [14]. Table 4 summarises the 
key data from EUROASPIRE I and II as compared to the DETECT results. Although 
considerable improvement in the prescription rates of beta blockers, ACE inhibitors, and 
statins occurred between 1995/1996 (EUROASPIRE I) and 1999/2000 (EUROASPIRE II), 
the corresponding prescription rates in Germany in 2003 (DETECT) remained below the 
European average, especially in terms of prescriptions of antiplatelet medications, beta 
blockers, and statins (Table 4). In the UK, Brady et al. [15] observed similar prescription rates 
of antiplatelet agents, but clearly lower prescription rates of beta blockers (21.4%), ACE 
inhibitors (13.4%), and statins (16.2%) in 24 431 patients with a diagnosis of CAD in primary 
care.  
 
Several publications have reported that men receive adequate treatment for CAD more often 
than women [16–18]. This study also shows lower prescription rates of beta blockers, ACE 
inhibitors, antiplatelet agents, and statins in women than in men, even though the prevalence 
rates of diabetes mellitus, hypertension, and hyperlipidaemia are similar in both genders. This 
result indicates a bias in prescription behaviour between male and female patients treated in 
primary care [19]. One reason may be that physicians in general considered the male patient 
to be at higher risk than the female patient [16]. On the other hand, female CAD patients 
received nitrates more often than male CAD patients, possibly reflecting their lower rates of 
PCI (16.0% vs 29.5%) and lower rates of bypass surgery (9.8% vs 23.1%). The higher rates of 
AT1 receptor inhibitors may possibly be related to a higher incidence of ACE-inhibitor side 
effects in women [20]. The debate regarding the difference in drug prescriptions between 
CAD patients with social health care insurance and private insurance is ongoing. Although the 
cost-containment restrictions (“medication budget”) for primary care physicians in Germany 
might explain the documented failure of guideline-oriented medications, the undertreatment 
even with acetylsalicylic acid shows that economic restrictions are not the sole explanation.  
 
The prescription rates of all drugs essential to improving prognosis of patients with CAD is 
correlated with the number of comorbidities (diabetes, hypertension, hyperlipidaemia). This 
situation reflects the fact that doctors are aware of the increasing risk these patients have for 
further cardiovascular events. On the other hand, even coronary patients with no comorbidity 
do need the full combination of antiplatelet agents, statins, beta blockers, and ACE inhibitors/ 
AT1 receptor antagonists. Taking this need into account, the prescription rates for these 
patients were remarkably low, ranging between 7.5% and 42.7%. Furthermore, in patients 
with one or more comorbidities, room for improvement still exists in secondary preventive 
drug treatment.  
 
Revascularisation rates 
 
Many studies report lower revascularisation rates in women with CAD or acute coronary 
syndrome than in men with similar conditions [21–24]. These findings were confirmed by 
DETECT. Bertoni et al. [25] reported lower rates of coronary bypass surgery for women in 
the United States between 1995 and 2001, whereas the rates of catheterisation-based 
procedures were similar for both genders. Patients with private health care insurance in our 
study received PCI and coronary bypass surgery more often than CAD patients with social 
health insurance. This result is consistent with other studies that have found that insurance 
status appears to affect treatment in patients with acute myocardial infarction [26, 27].  
 
Of course, one should keep in mind that lifestyle changes also play an important role in 
secondary prevention of coronary heart disease. Patients with established coronary heart 
disease are encouraged to stop smoking tobacco, make healthy food choices, increase physical 
activity, avoid excess weight, and reduce any existing excess weight [1]. 
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